Announcement on the engagement of the Company's Audit Institution for the Year 2020
Release time:
2021-05-20
证券代码:600668 证券简称:尖峰集团 公告编号:2020-011
浙江尖峰集团股份有限公司
关于聘请公司2020年度审计机构的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示
● 拟聘任的会计师事务所名称:天健会计师事务所(特殊普通合伙)
● 原聘任的会计师事务所名称:不适用
● 变更会计师事务所的简要原因及前任会计师的异议情况:不适用
一、拟聘任会计师事务所的基本情况
(一)机构信息
1、基本信息
机构名称:天健会计师事务所(特殊普通合伙)
成立日期:2011 年7月18日
注册地址:浙江省杭州市西湖区西溪路 128 号6楼
执业资质:注册会计师法定业务、证券期货相关业务、H股企业审计业务、中央企业审计入围机构、金融相关审计业务、从事特大型国有企业审计资格、军工涉密业务咨询服务、IT审计业务、税务代理及咨询、美国公众公司会计监督委员会(PCAOB)注册事务所、英国财务汇报局(FRC)注册事务所等。
是否曾从事证券服务业务:是
2、人员信息
首席合伙人:胡少先
合伙人数量:204 人
2019 年末从业人员类别及数量:从业人数 5603人;注册会计师1,606 人,其中从事过证券服务业务的注册会计师 1,000人以上
注册会计师人数近一年变动情况:新注册 355人,转入98人,转出 255人
3、业务规模
2019 年度业务收入:22亿元
2019 年度净资产金额:2.7亿元
2019 年度上市公司年报审计情况:403家上市公司年报审计客户;收费总额4.60亿元;涉及的主要行业包括:制造业,信息传输、软件和信息技术服务业,批发和零售业,房地产业,文化、体育和娱乐业,电力、热力、燃气及水生产和供应业,建筑业,交通运输业,金融业,租赁和商务服务业,水利、环境和公共设施管理业,科学研究和技术服务业,农、林、牧、渔业,住宿和餐饮业,教育,综合,采矿业等;资产均值约103亿元。
4、投资者保护能力
职业风险基金累计已计提:1亿元以上
购买的职业保险累计赔偿限额:1亿元以上
相关职业风险基金与职业保险能够承担正常法律环境下因审计失败导致的民事赔偿责任
5、独立性和诚信记录
天健会计师事务所(特殊普通合伙)不存在违反《中国注册会计师职业道德守则》对独立性要求的情形,近三年诚信记录如下:
|
类型 |
2017年度 |
2018年度 |
2019年度 |
|
刑事处罚 |
无 |
无 |
无 |
|
行政处罚 |
无 |
无 |
无 |
|
行政监管措施 |
2次 |
3次 |
5次 |
|
自律监管措施 |
1次 |
无 |
无 |
(二)项目成员信息
1、人员信息
|
项目组成员 |
姓名 |
执业资质 |
从业经历 |
是否兼职上市公司独立董事 |
是否从事过证券服务业务 |
|
项目合伙人(拟签字注册会计师) |
毛晓东 |
中国注册会计师、税务师 |
1996年至今,从事审计相关证券服务工作,具备相应专业胜任能力。 |
无 |
是 |
|
拟质量控制复核人 |
毛育晖 |
中国注册会计师 |
1994年至今,从事审计相关证券服务工作,具备相应专业胜任能力。 |
无 |
是 |
|
拟签字注册会计师 |
吴学友 |
中国注册会计师、税务师 |
2008年至今,从事审计相关证券服务工作,具备相应专业胜任能力。 |
无 |
是 |
2、上述相关人员的独立性和诚信记录情况
上述人员不存在违反《中国注册会计师职业道德守则》对独立性要求的情形,近三年诚信记录如下:
|
类型 |
2017年度 |
2018年度 |
2019年度 |
|
刑事处罚 |
无 |
无 |
无 |
|
行政处罚 |
无 |
无 |
无 |
|
行政监管措施 |
无 |
无 |
无 |
|
自律监管措施 |
无 |
无 |
无 |
(三)审计收费
2020 年度天健拟收取财务报告审计及内部控制审计费用合计不超过人民币150万元。该笔费用参照有关规定,以业务量为衡量标准,请股东大会授权董事会与该所谈判为准。审计期间的食、宿等费用由公司承担。
二、拟续聘会计事务所履行的程序
(一)董事会审计委员会履职情况及审查意见
公司第十届董事会审计委员会2020年度第一次会议审议通过了关于聘请公司2020年度审计机构的议案,认为该所在接受聘请并在公司2019会计年度结束后,按照本公司年度报告的编制、披露的时间要求,认真组织、开展本公司2019年度的审计工作,并按与本委员会商定的审计工作时间安排提供书面的《2019年度审计计划》;在审计工作中严格遵循国家法律、法规,保持了独立性,做到了审计监督的客观性、公正性、权威性和有效性。
董事会审计委员会发表书面审查意见如下:
天健会计师事务所有限公司具有证券、期货从业资格,公司上市以来一直聘请该所为财务报告的审计机构。该所对公司的情况熟悉了解并工作严谨,决定向董事会推荐续聘该所为公司2020年度财务报告及内部控制审计的审计机构。
(二)上市公司独立董事关于本次聘任会计事务所的事前认可及独立意见
公司独立董事已就本次续聘会计师事务所事项发表了同意的事前认可意见,并发表了独立意见如下:
天健会计师事务所有限公司在接受聘请并在公司2019会计年度结束后,按照本公司年度报告的编制、披露的时间要求,认真组织、开展本公司2019年度的审计工作,并按与本委员会商定的审计工作时间安排提供书面的《2019年度审计计划》;在审计工作中严格遵循国家法律、法规,保持了独立性,做到了审计监督的客观性、公正性、权威性和有效性。
该所具有证券、期货从业资格,公司上市以来一直聘请该所为财务报告的审计机构。该所对公司的情况熟悉了解并工作严谨。我们同意续聘该所为公司2020年度财务报告及内部控制审计的审计机构。
(三)董事会会议的召开、审议和表决情况
2020年4月24日,公司以现场与通讯表决相结合的方式召开了第十届董事会第14次会议,公司现有八名董事,全体董事亲自参加了会议,符合《公司法》和《公司章程》的有关规定,所做决议合法有效。会议由蒋晓萌董事长主持,经审议与表决,以8票同意、0票反对、0票弃权,审议通过了关于聘请公司2020年度审计机构的议案。
(四)本次聘任会计师事务所事项尚需提交公司股东大会审议,并自公司股东大会审议通过之日起生效。
特此公告
浙江尖峰集团股份有限公司
董事会
二〇二〇年四月二十八日
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11